Clinical trial · Observational
Role of PCGEM1 in Breast Cancer
Long Non-coding RNA: PCGEM1 as a Potential Marker for Tumorigenesis in Breast Cancer
NCT07562789CI-TRIAL-00110106not yet recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study examines certain molecular markers in breast cancer using blood and tissue samples from routine diagnostic biopsies. No extra procedures will be performed on patients. The goal is to improve understanding of disease mechanisms and identify potential targets for treatment
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| No Biologics | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- female breast cancer patients and matched control - no intervention
- interventionNames
- Device: No Biologics
Primary outcomes (1)
- measure
- Relative expression level of PCGEM1 marker in breast cancer tissue and blood sample
- timeFrame
- at base line
- description
- This outcome measures the relative expression level of PCGEM1 in breast cancer tissue and blood samples compared to control using quantitative real-time PCR (qRT-PCR). The results will be correlated with clinicopathological parameters.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age: 18 years and older. * Newly diagnosed patients with histopathological confirmation of the diagnosis of breast cancer at any stage. Exclusion Criteria: * Presence of any chronic diseases. * Previous history of breast cancer or other malignancies. * Evidence of distant metastasis at the time of diagnosis. * Prior treatment with chemotherapy or radiotherapy. * Incomplete clinical or laboratory data.
References
Publications (1)
- BACKGROUNDKumar S, Prajapati KS, Singh AK, Kushwaha PP, Shuaib M, Gupta S. Long non-coding RNA regulating androgen receptor signaling in breast and prostate cancer. Cancer Lett. 2021 Apr 28;504:15-22. doi: 10.1016/j.canlet.2020.11.039. Epub 2021 Feb 6. PMID 33556545